Karuna Therapeutics, Inc. (KRTX)

[kittu_123]

%22 to $96 perindi.... 440% surge.

where do you guys follow stocks info? forums/groups?

[Beardman]

B oston-based biotech Karuna Therapeutics (KRTX 1) said Monday that a novel combination pill achieved the main goal of a mid-stage clinical trial by reducing the acute psychosis and related symptoms experienced by patients with schizophrenia.

KarXT is an oral co-formulation of xanomeline, a muscarinic receptor agonist, and trospium, a muscarinic receptor antagonist, which acts through preferential stimulation of muscarinic receptors in the central nervous system.

The experimental combination antipsychotic drug from Karuna Therapeutics did well in a mid-stage clinical trial, reducing acute psychosis in patients with schizophrenia. It also had a more profound impact on hallucinations and delusions, and on emotional and social withdrawal, than placebo.

Antipsychotic medications have poor patient compliance issues, due largely to the unpleasant side effects they produce.

Karuna’s drug, called KarXT 1, targets the muscarinic acetylcholine receptors in the brain — a pathway that first was targeted by Eli Lilly in the 1990s. Lilly nixed the drug, called xanomeline, because of the intense nausea, dizziness, and vomiting that patients experienced.

Karuna also uses xanomeline, but it’s in combination with a second drug called tropsium that’s meant to mitigate the difficult side effects.

[nag_mama]

46 minutes ago, kittu_123 said:

%22 to $96 perindi.... 440% surge.

where do you guys follow stocks info? forums/groups?

https://stocktwits.com/symbol/KRTX

poddune koni vunte evening kalla 3 times ayyedi

[kittu_123]

4 hours ago, Beardman said:

B oston-based biotech Karuna Therapeutics (KRTX 1) said Monday that a novel combination pill achieved the main goal of a mid-stage clinical trial by reducing the acute psychosis and related symptoms experienced by patients with schizophrenia.

KarXT is an oral co-formulation of xanomeline, a muscarinic receptor agonist, and trospium, a muscarinic receptor antagonist, which acts through preferential stimulation of muscarinic receptors in the central nervous system.

The experimental combination antipsychotic drug from Karuna Therapeutics did well in a mid-stage clinical trial, reducing acute psychosis in patients with schizophrenia. It also had a more profound impact on hallucinations and delusions, and on emotional and social withdrawal, than placebo.

Antipsychotic medications have poor patient compliance issues, due largely to the unpleasant side effects they produce.

Karuna’s drug, called KarXT 1, targets the muscarinic acetylcholine receptors in the brain — a pathway that first was targeted by Eli Lilly in the 1990s. Lilly nixed the drug, called xanomeline, because of the intense nausea, dizziness, and vomiting that patients experienced.

Karuna also uses xanomeline, but it’s in combination with a second drug called tropsium that’s meant to mitigate the difficult side effects.

 I dint ask what is KRTX.  ilanti stocks info kaavalnte ekkada choostaru meeru ani adiga? it surge %400 in a day. i.e. $30 to $96 

[kittu_123]

4 hours ago, nag_mama said:

https://stocktwits.com/symbol/KRTX

poddune koni vunte evening kalla 3 times ayyedi

Yup. 

[nag_mama]

Myov ninna 6$ Eeroju 17$ ki vellindi ippudu 11.50$

 

[kittu_123]

1 hour ago, nag_mama said:

Myov ninna 6$ Eeroju 17$ ki vellindi ippudu 11.50$

 

ippude choosa. 

[Spartan]

Try your luck and invest in ABIOMED, Inc.  (ABMD) perutademo malli..

@kittu_123 @nag_mama

[kittu_123]

@Spartan Sure, will check it out.

[nag_mama]

18 hours ago, kittu_123 said:

ippude choosa. 

ARAV

[krishnote3]

they also drop value like that..just stay away..desi company ante inka stay away

[cup_saucer]

https://www.biopharmcatalyst.com/ 

 

check catalyst calendar.... learn what is their study and how much would be the impact.. not all calendars will raise the stock... so it is pure gamble.. they dont give hints before submitting the drug to FDA. so phases is also imp... KRTX and MYOV are in phase 3 i guess.